The SARS-Cov-2 infection pandemic has caused a large number of acute respiratory failuresand deaths across the world. Certain factors have been identified as associated with ahigher risk of developing a severe form and dying. Immunosuppression has been identifiedas a risk factor for progressing to a severe form.Lung transplant patients were particularly vulnerable during this period, with a highfrequency of respiratory compromise, sometimes progressing towards acute respiratorydistress syndrome and, at a later stage, towards fibrotic forms. The impact of theinfection on the immunological status of the patient and on the tolerance of thetransplant have been little studied. The various treatments implemented during thepandemic have rapidly evolved (immunotherapy, vaccination, convalescent plasmatransfusion, etc.) which may have modulated this risk. The evolution of respiratoryfunction may be linked to the respiratory infection itself, or to the severity ofrespiratory damage during the infection. It is therefore relevant to compare patientswith a moderate form of COVID-19 (non-intubated patients) to patients with severe forms,requiring invasive ventilation in intensive care. The evolution of respiratory functionafter infection has not yet been studied.